Discounted cash flow valuation of prizer inc.

Abstract

This thematic paper explores the intrinsic value of Pfizer Inc. (PFE) share price by using the discounted cash flow valuation method (DCF) to assess if a stock is overvalued or undervalued to empower investors to navigate the market more effectively. According to the DCF analysis in this paper, the implied share value of Pfizer is $48.96 per share, which is 39% higher than the latest stock price as of November 10, 2023. This suggests that Pfizer’s intrinsic value is higher than its market price, and the current price of $29.68 per share is undervalued. Hence, the recommendation is to “BUY”